• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
Attachment A Comments in Response to the Food and Drug Administration
Attachment A Comments in Response to the Food and Drug Administration

... correspond with those noted in the NPRMs. Improving Patient Information and Consent Issue : FDA regulatory requirements should ensure that patients are well-informed about the risks and benefits of experimental and investigational drugs and therapies before patients can consent to receive them. Disc ...
Network pharmacology - Center for Cancer Systems Biology
Network pharmacology - Center for Cancer Systems Biology

Reflection paper on the data requirements for - EMA
Reflection paper on the data requirements for - EMA

Generic Drugs - CN Pensioners` Association
Generic Drugs - CN Pensioners` Association

... A generic drug is an interchangeable version of a brand name product. Generic drugs contain the same active medicinal ingredient and are considered therapeutically equivalent to the brand name product although they may differ in shape and colour when compared to the brand name product. The most im ...
Trinity Research & Innovation-Licensing Opportunity A E
Trinity Research & Innovation-Licensing Opportunity A E

... Progablin is a blockbuster anticonvulsat drug, marketed as Lyrica, used to treat neuralgiac pain. A difficulty in its synthesis is ensuring that the right chiral enantiomer is formed. Trinity researchers have developed a new method to selectively synthesise the appropriate enatiomer of an immediate ...
Regulatory challenges of developing a combination product in a
Regulatory challenges of developing a combination product in a

... Evaluation & Research / Center for Drugs Evaluation & Research) ...
Reliable and complete reference on all drugs, health products
Reliable and complete reference on all drugs, health products

BIOM 255: Molecular basis of drug action and disease therapy
BIOM 255: Molecular basis of drug action and disease therapy

... What new efforts in pharmacotherapy and pharmacology are on the horizon? • In addition to “genetically informed” understanding of disease, drug development/prescribing, other aspects of pharmacotherapy that will likely change are: – ”New” disease/drug targets based on evolving information from gene ...
nektar - Moodle Lille 2
nektar - Moodle Lille 2

No Slide Title
No Slide Title

... Good Manufacturing Practice implemented in 1976 for the manufacture of products that are under FDA jurisdiction, including pharmaceuticals, biological products and medical devices. Current Good Manufacturing Practice ensures that finished products have the correct identity, strength, quality and pur ...
Prescribing information for paediatric medicines
Prescribing information for paediatric medicines

... If a paediatric indication has not been approved, the following text is suggested under a subheading ‘paediatric patients’: a. X is not recommended for use in children age Y due to data on safety and/or efficacy (the age should be specified)’ b. The experi ...
Walgreens Health Initiatives (WHI)
Walgreens Health Initiatives (WHI)

... under this Plan subject to any applicable PPO Deductibles and Co-insurance. NOTE: Coverage, limitations, and exclusions for prescription drugs will be determined through the Prescription Drug Card program elected by the Employer and will not be subject to any limitations and exclusions under the maj ...
XTL Biopharmaceuticals Announces New Patent Filing in U.S. for
XTL Biopharmaceuticals Announces New Patent Filing in U.S. for

... 5 Hacharoshet Street, Raanana, 43656, Israel Tel: +972 9 955 7080; email: ir@xtlbio.com ...
Slide 1
Slide 1

... protect human subjects • Fraud and unethical practices still occur today • The appearance of fraud or unethical behavior can be detrimental to the investigator and sponsor • Sponsors expect nuclear medicine investigators and study coordinators to be knowledgeable about the regulations and guidance d ...
Antibiotic PK/PD
Antibiotic PK/PD

... King Hussein Cancer Center Amman, Jordan ...
Getting the Big Picture Clinical Trials
Getting the Big Picture Clinical Trials

... simply because they help diabetics control blood sugar levels — the standard for more than 80 years. •Instead, the F.D.A. now insists that drugmakers conduct trials lasting at least two years to show that their medicines do not hurt the heart and that they improve the quality or length of diabetics’ ...
No Slide Title
No Slide Title

... Phase III (2-6 years) - establishes efficacy and adverse effects from long-term use with several thousand patients New Drug Application (NDA) submitted to FDA (4-36 months) Phase IV - results after drug is on market ...
What are Drugs? - Noadswood Science
What are Drugs? - Noadswood Science

... campaigners hit the streets. According to one Oxford academic, a war is looming over "scientific freedom" and the "future of progress", no less. And this Saturday the battle for and against testing will shift from the city's dreaming spires to its historic streets. Over the past two years there have ...
Michelle Quinlan`s PPT file
Michelle Quinlan`s PPT file

Follicum – Click to
Follicum – Click to

CAM Herbs - American Academy of Pediatrics
CAM Herbs - American Academy of Pediatrics

... By the end of this presentation, participants will be able to: • Describe the role of herbal medicine in the overall scheme of health care • Identify at least one herbal product they already use • Confidently and effectively ask patients about their use of herbal products • Use evidence-based resour ...
Calcipotriol and Betamethasone Dipropionate for the Treatment of
Calcipotriol and Betamethasone Dipropionate for the Treatment of

... A recent study documented the effects of the molecules, in isolation and in combination, when used on psoriatic skin.8 Calcipotriol alone had a major effect on the proliferation marker Ki-67 and differentiation marker keratin-10 (K-10) while reducing T-cell subsets CD 45RO (+) and CD8 (+). Betametha ...
Transdermal Delivery Systems
Transdermal Delivery Systems

... 3. List the limitations on the types of drugs which can be administered by first-generation transdermal delivery systems. Explain why much of the drug is wasted, and how this is commercially feasible. 4. Draw the structures of the following drugs and circle the functionalities capable of ionization ...
harnessing-the-gut-microbiome-presentation
harnessing-the-gut-microbiome-presentation

Shana`s Seminar
Shana`s Seminar

... effects one year after is approval by the FDA. Initial studies approved this drug to safely be used for 14 different uses and no harmful side effects were detected. Hundreds of people suffered from liver disease and the drug had to immediately be recalled. Effects of this type of error included many ...
< 1 ... 151 152 153 154 155 156 157 158 159 ... 193 >

Biosimilar

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product which is a copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original ""innovator"" products, and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and may be quite sensitive to changes in manufacturing processes. Follow-on manufacturers do not have access to the originator's molecular clone and original cell bank, nor to the exact fermentation and purification process, nor to the active drug substance. They do have access to the commercialized innovator product.Drug related authorities such as European Medicines Agency (EMA), Food and Drug Administration (FDA), and Health Canada hold their own guidance on requirements for demonstration of the similar nature of two biological products in terms of safety and efficacy. According to them, analytical studies that demonstrate that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; animal studies (including the assessment of toxicity); and a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product.In case of a monoclonal antibody-containing medicinal product, such as Remsima, extensive physicochemical and biological characterization for it and its reference product Remicade was conducted in order to demonstrate their highly similar properties. Consequently, EMA have granted a marketing authorisation for only a few numbers of biosimilars since 2006 including a monoclonal antibody which is recently approved. Meanwhile, on March 6, 2015, the FDA approved the United States's first biosimilar product, the biosimilar filgrastim Zarxio.
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report